Hirohisa Omiya
Taisho Pharmaceutical (Japan)(JP)
Publications by Year
Research Areas
Diabetes Treatment and Management, Pancreatic function and diabetes, Metabolism, Diabetes, and Cancer, Diabetes Management and Research
Most-Cited Works
- → Effects of luseogliflozin, a sodium–glucose co‐transporter 2 inhibitor, on 24‐h glucose variability assessed by continuous glucose monitoring in J apanese patients with type 2 diabetes mellitus: a randomized, double‐blind, placebo‐controlled, crossover study(2015)49 cited
- → Sodium‐glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low‐carbohydrate diet(2015)27 cited
- → Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus(2016)16 cited
- → Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study(2016)6 cited